Latest News

Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.

The therapy also received orphan drug designation from the FDA.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

Paul Melmeyer, MPP, executive vice president, public policy and advocacy, Muscular Dystrophy Association, explains how adding Duchenne muscular dystrophy to the Recommended Unified Screening Panel reshapes early diagnosis, treatment timing, and family counseling.

Published phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.

The director of Cleveland Clinic's Gamme Knife Center and Head Section of Spine Tumors writes about how stereotactic radiosurgery has transformed modern neurology and neurosurgery

In the middle of 2026, the company is planning to submit a BLA for RGX-202 via an accelerated approval pathway.

A trio of clinician authors provided insights on a recently published paper assessing youths with refractory epilepsy and ways to combat depressive symptoms.

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

Annette Lenger-Gould, MD, PhD, lead for clinical and translational neuroscience at Kaiser Permanente, discusses findings and significance from a recently published trial assessing rituximab in patients with relapsing multiple sclerosis.

The FDA approved Sentynl Therapeutics’ copper histidinate for the treatment of pediatric Menkes disease, a rare genetic neurodegenerative disorder, following an earlier complete response letter.

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.